SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genzyme Tissue Repair (GZTR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Knighty Tin who wrote (2543)8/5/2000 10:56:38 AM
From: Exacctnt  Read Replies (1) of 2553
 
Mike, I'm glad to see GZTR is still one of your favorites. What is your take on the current pricing for GZTR GZSP and BXM? With the proposed merger price paid for BXM being $37 a share, its stock price is far from that figure. Will it close the gap once the merger passes muster from the government and shareholders, or, is it simply an indication that the deal won't go through in its current structure?

What about GZTR? If the merger doesn't occur, do you see GZTR rallying?

Regards
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News